Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)

This study has been completed.
Information provided by (Responsible Party):
Steba Biotech S.A. Identifier:
First received: March 1, 2011
Last updated: April 17, 2016
Last verified: April 2016

The aims of this study are:

  • to assess the impact of TOOKAD® Soluble-Vascular Targeted Photodynamic Therapy (VTP) on the rate of absence of definite cancer using patients on active surveillance as a comparison (co-primary objective A) and
  • to determine the difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men who undergo TOOKAD® Soluble-VTP compared to men on active surveillance (co-primary objective B).

Condition Intervention Phase
Prostate Cancer
Drug: TOOKAD® Soluble
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance

Resource links provided by NLM:

Further study details as provided by Steba Biotech S.A.:

Primary Outcome Measures:
  • Co-primary endpoint 'A': Rate of absence of definite cancer using patients on active surveillance as a comparison. [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
    Histological changes are assessed using biopsies or any other pathology result obtained during the study planned or not.

  • Co-primary endpoint 'B': Difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer. [ Time Frame: Over 24 months follow-up. ] [ Designated as safety issue: No ]

    Moderate or higher risk is defined as the observation of:

    • More than 3 cores positive for cancer when considering all histological examination available during follow-up of study;
    • or any Gleason primary or secondary pattern 4 or more;
    • or at least one cancer core length greater than 5 mm;
    • or PSA>10ng/mL ( in 3 consecutive measures);
    • or any T3 prostate cancer,
    • or metastasis;
    • or prostate cancer related death

Secondary Outcome Measures:
  • The rate of additional prostate cancer radical therapy [ Time Frame: Over 24 months follow-up ] [ Designated as safety issue: No ]
  • Total number of cores positive for cancer [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
  • The rate of incontinence, erectile dysfunction, urinary symptoms [ Time Frame: Randomisation visit, Day 7 after VTP , Month 3, Month 6, Month 9, Month 12, Month 24 ] [ Designated as safety issue: Yes ]
  • The rate of adverse events [ Time Frame: Screening-Month 24 ] [ Designated as safety issue: Yes ]
  • The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death [ Time Frame: Screening-Month 24 ] [ Designated as safety issue: Yes ]
  • The overall quality of life will be recorded for potential utility and descriptive studies. [ Time Frame: Randomisation visit; Month 12; Month 24 ] [ Designated as safety issue: Yes ]

Enrollment: 413
Study Start Date: February 2011
Study Completion Date: August 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TOOKAD® Soluble
TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
Drug: TOOKAD® Soluble
TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Other Name: WST11
No Intervention: Active Surveillance
Active surveillance is one of the management strategy in men who have low-risk prostate cancer

Detailed Description:

This is a Phase 3, multicentre, open label, randomised controlled study in subjects diagnosed with low risk prostate cancer on TransRectal Ultrasound (TRUS) guided biopsy.

Subjects will be randomised to either Active Surveillance or TOOKAD® Soluble VTP. Subjects will remain in the study for approximately 24 months following randomisation. A total of 400 subjects will be entered into the study; 200 will receive Active Surveillance and 200 will receive TOOKAD® Soluble-VTP.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects will be eligible for inclusion in the study if all of the following criteria are met:

  1. Low risk prostate cancer diagnosed using one transrectal ultrasound guided biopsy (TRUS)using from 10 to 24 cores performed less than 12 months prior to enrolment, and showing the following:

    • Gleason 3 + 3 prostate adenocarcinoma as a maximum,
    • Two (2) to three (3) cores positive for cancer
    • A maximum cancer core length of 5 mm in any core.
  2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease permitted)
  3. Serum prostate specific antigen (PSA) of 10 ng/mL or less
  4. Prostate volume equal or greater than 25 cc and less than 70 cc.
  5. Male subjects aged 18 years or older.

Exclusion Criteria:

Subjects will not be eligible for the study if meeting any of the following criteria:

  1. Unwillingness to accept randomisation to either of the two arms of the study
  2. Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy.
  3. Any surgical intervention for benign prostatic hypertrophy
  4. Life expectancy less than 10 years.
  5. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure.
  6. Participation in another clinical study or recipient of an investigational product within 1 month of study entry.
  7. Subject unable to understand the patient's information document, to give consent or complete the study tasks.
  8. Subject in custody and or in residence in a nursing home or rehabilitation facility
  9. Contra-indication to Magnetic resonance Imaging (MRI) (e.g., pacemaker, history of allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI (e.g., hip prosthesis)
  10. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the TOOKAD® Soluble VTP procedure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01310894

  Show 51 Study Locations
Sponsors and Collaborators
Steba Biotech S.A.
Principal Investigator: Mark Emberton, Professor University College of London Hospital , United Kingdom
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Steba Biotech S.A. Identifier: NCT01310894     History of Changes
Other Study ID Numbers: CLIN1001 PCM301 
Study First Received: March 1, 2011
Last Updated: April 17, 2016
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Finland: Finnish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Italy: The Italian Medicines Agency
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Switzerland: Swissmedic
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: The data are available in case report form for each patient

Keywords provided by Steba Biotech S.A.:
Prostatic Disease
Genital Neoplasm,male
Urogenital neoplasm
Genital disease,male
Male urogenital disease
Neoplasms by site
Prostatic neoplasm

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on January 18, 2017